Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
about
Vaccines for preventing influenza in healthy adultsSafety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patientsCharacterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.Seasonal influenza vaccination and technologies.A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.Considerations for the rapid deployment of vaccines against H7N9 influenza.Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses.Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza.Telephone monitoring of adverse events during an MF59®-adjuvanted H5N1 influenza vaccination campaign in Taiwan.Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthOverview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Traditional and new influenza vaccinesEffects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.Old and new adjuvants.Heterologous Immune Responses to Influenza Vaccine in Kidney Transplant Recipients.An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.Influenza vaccines: Evaluation of the safety profile.MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico.Systems Biology-Based Platforms to Accelerate Research of Emerging Infectious Diseases.
P2860
Q24197955-B3628833-763E-4EC6-83C1-8FA65BF75459Q30210481-FD811C81-ED53-434B-8885-8CC23C3D0864Q30360436-5559AF61-172A-479D-AC21-4165D5F53F00Q30360897-6BA091E4-E6C2-4C85-89FD-FA8B3EF40B2DQ30363098-6A71971A-56EB-4C98-9E47-CD58385A1B4BQ30364635-58FE3EEF-DF5A-4156-AEC7-7EFBDA822CEFQ30368239-DE086C75-BEF8-4770-9B34-F746223F2F66Q30368247-5B4ACBD5-D280-4C1B-A3A5-20E587442A91Q30368474-B57C17A5-467B-464A-BF6A-CC2BA998ABBFQ30372521-4BED38E9-D964-4639-9F2D-7059FC72E571Q30401247-8ED137BF-FDA1-4306-9BE5-7A10199176BDQ30424161-4E46941D-29EE-4268-A8BF-0583DC2E60F6Q34271475-079D6C99-9CBE-4E62-9930-C777D2DBD52CQ34497705-C373DC42-4D5C-46FE-A246-F05EC45F1197Q35826733-B8EAAEA4-FDFC-4AFE-A211-4D8C823BC139Q37035833-1496FD06-3581-42AC-BCCC-BF5192DA98B0Q37093487-E42A7673-F53F-4578-9FEB-8B972F391CFDQ39451745-2402052C-CE51-42FD-BCC8-365710F37AB7Q40617701-4D9D4523-756B-445F-B84A-9D4C81CF9A5EQ40782869-7CC181BE-5EB7-47F2-811C-523C8A14C8D0Q49345779-A5B5C695-05A1-47A4-8918-A4CB76188060Q50024815-FF15A942-9E6D-46AE-9D79-B647C5AEB4B9Q50049541-DC1BBEB4-68CF-4FCC-BC2C-6F74B9BE5A9A
P2860
Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety and immunogenicity of a ...... ine in adults and the elderly.
@ast
Safety and immunogenicity of a ...... ine in adults and the elderly.
@en
type
label
Safety and immunogenicity of a ...... ine in adults and the elderly.
@ast
Safety and immunogenicity of a ...... ine in adults and the elderly.
@en
prefLabel
Safety and immunogenicity of a ...... ine in adults and the elderly.
@ast
Safety and immunogenicity of a ...... ine in adults and the elderly.
@en
P2093
P1433
P1476
Safety and immunogenicity of a ...... ine in adults and the elderly.
@en
P2093
Aino Forstén
Astrid Borkowski
Giovanni Della Cioppa
Jenny Beygo
Karl-Heinz Herbinger
Mariaviviana Bennati
Nicola Groth
Timo Vesikari
P304
P356
10.1016/J.VACCINE.2011.12.009
P407
P577
2011-12-20T00:00:00Z